-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Nurix Therapeutics, Lowers Price Target to $33

Benzinga·10/13/2026 12:51:05
Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $34 to $33.